Physician profile
Mark F Pyfer
NPI 1134198096
$151,208.49
in general payments reported to CMS, 2019-2025
38 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $21K · 2021: $11K · 2022: $15K · 2023: $11K · 2024: $38K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Food and Beverage: $8,595 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,400 · Travel and Lodging: $2,217 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,600.00 |
| Food and Beverage | $8,594.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,400.00 |
| Travel and Lodging | $2,216.69 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $44,040.63 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $37,469.92 | 2019-2025 | Catalys System, Tecnis Simplicity, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $14,633.64 | 2022-2023 | Omidria, Omidria |
| Sight Sciences, INC. | $12,025.42 | 2019-2025 | Omni Surgical System |
| Eyepoint US, INC. | $8,229.21 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $7,232.75 | 2020-2022 | |
| Alcon Vision LLC | $5,030.51 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Tarsus Pharmaceuticals, INC. | $4,237.25 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $3,527.25 | 2020-2025 | |
| Abbvie INC. | $3,081.30 | 2022-2025 | |
| Carl Zeiss Meditec USA, INC. | $2,296.99 | 2022-2024 | Iolmaster 700, Artevo 800 |
| Rxsight INC | $2,122.06 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $1,565.35 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $922.83 | 2019-2025 | Cequa |
| Allergan, INC. | $710.97 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pyfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.